Navigation Links
Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2014

UNION CITY, Calif., July 25, 2013 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the first fiscal quarter ended June 30, 2013.

Quarterly highlights include:

  • Total veterinary instrument sales of $7.6 million, up 14% over last year's comparable quarter.
  • Total veterinary instrument sales of 1,103 units, up 13% over last year's comparable quarter.
  • Total sales in the veterinary market of $36.4 million, up 12% over last year's comparable quarter.
  • North America revenues of $34.7 million, up 4% over last year's comparable quarter.
  • Revenues of $43.2 million, up 3% over last year's comparable quarter.
  • Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of $2.2 million, up 157% over last year's comparable quarter.
  • Diluted EPS of $0.14, up 8% over last year's comparable quarter.
  • Cash, cash equivalents and short- and long-term investments as of June 30, 2013 of $103.8 million, an increase of $8.6 million from March 31, 2013.
  • Quarterly Results:  For the fiscal quarter ended June 30, 2013, Abaxis reported revenues of $43.2 million, as compared with revenues of $42.0 million for the comparable period last year, an increase of 3 percent.  Revenues from sales of instruments, which include chemistry analyzers, hematology instruments, VSpro specialty analyzers and i-STAT analyzers, decreased by $1.2 million or 12 percent, compared to the same period last year.  Revenues from sales of consumables, which include reagent discs, hematology reagent kits, VSpro specialty cartridges, i-STAT cartridges and rapid tests, increased by $1.1 million, or 4 percent, over the same period last year.  Abaxis reported net income of $3.2 million for the fiscal quarter ended June 30, 2013, compared to $2.9 million for the same period last year, an increase of 13 percent.  Abaxis' effective tax rate in the quarter ended June 30, 2013 was 36 percent, compared to 37 percent for the same period last year.  Abaxis reported diluted net income per share of $0.14 (calculated based on 22,571,000 shares) for the three-month period ended June 30, 2013, compared to $0.13 per share (calculated based on 22,217,000 shares) for the same period last year. 

    Other Reported Information:  Total sales in the medical market for the first quarter of fiscal 2014 were $6.0 million, a decrease of 29 percent compared to the same period last year.  Medical sales worldwide, excluding sales to the U.S. government, during the first quarter of fiscal 2014 were $5.7 million, a decrease of 27 percent compared to the same period last year.  Total sales in the veterinary market for the first quarter of fiscal 2014 were $36.4 million, an increase of 12 percent, compared to the same period last year.  Total medical and veterinary reagent disc sales for the first quarter of fiscal 2014 were $22.8 million, a decrease of 3 percent compared to the same period last year.  Total operating expenses decreased by $1.8 million, or 10 percent, compared to the same period last year.  Non-cash compensation expense recognized for share-based awards during the first quarter of fiscal 2014 was $2.2 million, compared to $1.8 million for the same period last year.  Abaxis' Board of Directors has approved approximately $12 million increase to its existing share repurchase program, to a total of $67 million.

    Clint Severson, chairman and chief executive officer of Abaxis, said, "The results for the quarter continue to reflect the impact of our transition from a direct sales model to strategically partnering with industry leading distributors to sell our products into the expanded markets that these partners have developed.  In that regard, we are very pleased with the 12% increase in our worldwide veterinary business versus the comparable quarter last year.  Our distribution partner in the veterinary business, MWI Veterinary Supply, Inc., has done an outstanding job in placing Abaxis products since they commenced their marketing and sales efforts.  In the medical market, our distributor, Abbott Point of Care, Inc., is making progress in integrating the Piccolo analyzer and its consumables into their sales process.  While they are still in the early stages of their roll-out, their sales are increasing, and we fully expect that Abbott will ultimately surpass the historical medical market sales levels of our in-house sales team."

    "We continue to gain traction in attracting new customers, and serving our existing customers at the AVRL.  On a year-over-year basis, revenue at the AVRL increased 157%.  Additionally, sales of veterinary consumables other than veterinary reagent discs, which represent an important component of our recurring revenue stream, were up 32% compared to last year's first quarter.  Overall, we are pleased with the progress being achieved and expect improved operational and financial results as we move through fiscal 2014 and beyond." 

    Mr. Severson concluded, "The financial condition of the company remains strong with more than $100 million in cash, cash equivalents and short- and long-term investments.  The strength of our balance sheet continues to be very important as we successfully operate in the challenging global economic environment."

    Conference CallAbaxis has scheduled a conference call to discuss its financial results at 4:15 p.m. Eastern Time on Thursday, July 25, 2013.  Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet webcast, which is available in the Investor Relations section of the company's website at  A replay of the call will be available by visiting for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, confirmation code 10031352, through August 1, 2013.  This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at

    About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia and Lyme disease.  Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  For more information, visit

    Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release.  Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares.  Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.

    Forward Looking StatementsThis press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to risks related to transitioning our medical sales to Abbott, losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products and services, the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy.  Readers should also refer to the section entitled "Risk Factors" in Abaxis' annual report on Form 10-K, recent quarterly reports on Form 10-Q and Abaxis' other periodic reports filed with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.

    Financial Tables to FollowABAXIS, INC.Condensed Consolidated Statements of Income(In thousands, except per share data)(Unaudited)Three Months EndedJune 30,20132012Revenues


    42,014Cost of revenues


    19,165Gross profit


    22,849Operating expenses:Research and development 


    2,965Sales and marketing 


    11,769General and administrative


    3,322Total operating expenses


    18,056Income from operations


    4,793Interest and other income (expense), net


    (230)Income before income tax provision


    4,563Income tax provision


    1,699Net income


    2,864Net income per share:  Basic net income per share


    .13  Diluted net income per share


    .13Shares used in the calculation of net income per share:  Weighted average common shares outstanding - basic


    21,817  Weighted average common shares outstanding - diluted


    22,217 ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)June 30,March 31,20132013Current assets: Cash and cash equivalents


    54,910 Short-term investments


    23,354 Receivables, net


    40,005 Inventories


    26,786 Prepaid expenses and other current assets


    3,319 Net deferred tax assets, current


    4,589Total current assets 


    152,963Long-term investments


    17,000Investment in unconsolidated affiliate


    2,613Property and equipment, net


    25,330Intangible assets, net


    3,122Net deferred tax assets, non-current


    643Other assets


    92Total assets


    201,763Current liabilities: Accounts payable


    8,123 Accrued payroll and related expenses


    6,261 Accrued taxes


    440 Other accrued liabilities


    2,838 Deferred revenue


    1,362 Warranty reserve


    995Total current liabilities


    20,019Non-current liabilities: Deferred rent


    729 Deferred revenue


    3,750 Warranty reserve


    389 Notes payable, less current portion


    682Total non-current liabilities


    5,550Total liabilities


    25,569Shareholders' equity: Common stock


    121,019 Retained earnings 


    55,133 Accumulated other comprehensive income


    42Total shareholders' equity


    176,194Total liabilities and shareholders' equity


    201,763The following table presents our calculation of operating income per share for the three months ended June 30, 2013 and 2012.Operating Income Per Share(In thousands, except per share data)Three Months EndedJune 30,20132012Income from operations


    4,793Shares used in the calculation of operating income per share:  Weighted average common shares outstanding - basic


    21,817  Weighted average common shares outstanding - diluted


    22,217Operating income per share - basic


    .22Operating income per share - diluted



    The following table presents our revenues by source for the three months ended June 30, 2013 and 2012.Revenues by Geographic Region and Customer Group(In thousands)Three Months EndedJune 30,20132012Revenues by Geographic RegionNorth America




    8,850Total revenues


    42,014Revenues by Customer Group (1)Medical Market


    8,449Veterinary Market




    974Total revenues



    (1) Reclassifications of prior period revenues amounts by customer group have been made to conform to the current period presentation.  Effective in the fourth quarter of fiscal 2013, we reclassified certain revenues from our unallocated category to its respective business segment, either medical market or veterinary market.

    SOURCE Abaxis, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Abaxis, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    2. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
    3. Abaxis To Report First Quarter Fiscal Year 2013 Financial Results Thursday, July 26, 2012
    4. Abaxis Reports Financial Performance For The First Quarter Of Fiscal 2013
    5. Abaxis, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
    6. Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference
    7. Abaxis, Inc. to Present at CL Kings 10th Annual Best Ideas Conference 2012
    8. Abaxis, Inc. to Present at UBS Global Life Sciences Conference
    9. Abaxis Announces the Launch of Kidney Profile Plus Panel
    10. Abaxis Announces Exclusive Distribution Agreement with Abbott
    11. Abaxis, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
    Post Your Comments:
    (Date:10/7/2017)... IRVING, Texas , Oct. 6, 2017   ... industry with more than $100 billion in purchasing power, ... industry news and information. The Newsroom is ... chain and industry trends, infographics, expert bios, news releases, ... Besides having access to a wealth of resources at ...
    (Date:10/4/2017)... , Oct. 4, 2017  According to the Centers for Disease Control ... of October . PhysicianOne Urgent Care is helping communities across ... NY , by offering no-cost* flu shots through the end of ... by certain health insurance regulations. ... best time to get a flu shot is by the end of ...
    (Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
    (Date:10/12/2017)... ... October 12, 2017 , ... In ... taxes a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, ... overseas retirement havens have extremely low property-tax rates, which contributes to the relatively ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward ... and other leading institutions in announcing the launch of the Leadership Circle ... way animals are raised for food. , Founding members of the Leadership Circle ...
    (Date:10/12/2017)... , ... October 12, 2017 , ... ... manufacturer, has expanded its executive staff with the addition of industry sales leader, ... role, Slott will develop the national distribution and sales network, direct the efforts ...
    Breaking Medicine News(10 mins):